Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04381728
Other study ID # PREG1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 18, 2019
Est. completion date March 15, 2021

Study information

Verified date November 2021
Source Womed
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intrauterine adhesions (IUA) are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complication and infertility. Womed Leaf is a medical device specifically designed for intrauterine use that prevents intra-uterine adhesions. It is a film that acts as a mechanical barrier to keep uterus walls separated during healing. It is then naturally discharged through the cervix and vagina in less than 30 days. The PREG1 clinical investigation is designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy.


Description:

Intrauterine adhesions (IUA) are defined as "fibrous strings at opposing walls of the uterus and/or cervix leading to partial or complete obliteration of the cavity". IUAs are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complications and infertility. Womed Leaf™ is a sterile, degradable polymer film specifically design for intrauterine use. It is inserter in the uterus like an intrauterine device. Once released it will self-deploy into the uterine cavity to form a mechanical barrier keeping uterus walls separated during healing, for several days, thus preventing the formation or recurrence of intrauterine adhesions. It is degraded and discharged naturally through the cervix and vagina in less than 30 days. The PREG1 clinical investigation is a prospective multicenter, single arm study, designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy in preventing IUA at second look hysteroscopy.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date March 15, 2021
Est. primary completion date March 15, 2021
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Women = 40 years AND no childbearing wish, OR history of permanent sterilization; - Subject scheduled for hysteroscopic myomectomy for one or more myoma(s) where one myoma is at least 10 mm in size (=10mm) as estimated by pre-operative ultrasound measurement of the largest diameter, - Hysterometry prior to device insertion = 6cm and = 9cm. - Subjects who are willing to provide a written informed consent as approved by the applicable Ethics Committee prior to participating in this clinical investigation. - Subjects who can comply with the study follow-up or other study requirements Exclusion Criteria: Pre-operative exclusion criteria: - Current pregnancy - Abnormal uterine cavity according to ESHRE classification I to VI, such as unicornis, bicornis, septate, duplex - Known or suspected endometrial hyperplasia - Medical history of cervical or endometrial cancer - Active pelvic infection or medical history of pelvic peritonitis - Intrauterine device in situ - Known contraindication or hypersensitivity to PEO or PLA, and to medications such as aspirin…. - Concurrent medical condition with a life expectancy of less than 12 months - Full endometrial ablation Per-operative exclusion criteria: - Adenomyosis - Inflammation (endometritis) - Abnormal uterine cavity - Hysterometry < 6cm or >9cm - Any complication during the intervention that is deemed to potentially interfere with the objective of the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Womed Leaf
Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.

Locations

Country Name City State
Belgium UZ Gent Gent
France CHU Nîmes Nîmes
France CHU Bicêtre (APHP) Paris
Netherlands Bergman Clinics Amsterdam
Netherlands Zaans Medical Center Amsterdam
Netherlands Isala Zwolle Zwolle

Sponsors (1)

Lead Sponsor Collaborator
Womed

Countries where clinical trial is conducted

Belgium,  France,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety (Adverse Events) The number and severity of polymer film related adverse event 30 days
Primary Efficacy (Rate of Patient With no IUA) Freedom from intrauterine adhesion At second look hysteroscopy between 4 and 8 weeks
Primary Efficacy (Intrauterine Adhesion Severity According to AFS Classification) Severity of IUAs according to American Fertility Society (AFS) classification systems of adhesions.
Pronostic classification => Hysteroscopy score Stade I (mild) => 1-4 Stade II (moderate) => 5-8 Stade III (severe) => 9-12
At second look hysteroscopy between 4 and 8 weeks
Primary Efficacy (Intrauterine Adhesion Severity According to ESGE Classification) Severity of IUAs according to European Society of Gynecological Endoscopy (ESGE) classification systems of adhesions.
I => Thin or filmy IUA easily ruptured by HSC sheath alone. Cornual areas normal II => Singular dense IUA connecting separate parts of the uterine cavity. Visualization of both tubal ostia possible. Cannot be ruptured by HSC sheath alone IIa => Occluding IUA only in the region of the internal cervical os. Upper uterine cavity normal III => Multiple dense IUA connecting separate parts of the uterine cavity. Unilateral obliteration of ostial areas of the tubes IV => Extensive dense IUA with (partial) occlusion of the uterine cavity. Both tubal ostial areas (partially) occluded Va => Extensive endometrial scarring and fibrosis in combination with grade I or grade II IUA with amenorrhea or pronounced hypomenorrhea Vb => Extensive endometrial scarring and fibrosis in combination with grade III or grade IV IUA with amenorrhea
At second look hysteroscopy between 4 and 8 weeks
Secondary Adverse Events Number of adverse events (AE) at 30 days 30 days
Secondary Device Technical Success Defined as the rate of success of the following 2 steps : insertion and release During operation: T=0
Secondary Womed Leaf Residuals Presence of Womed Leaf residuals in the uterus At second look hysteroscopy: 4-8 weeks
Secondary Womed Leaf Discharge Feedback : Time Interval in Days Between Surgery and Discharge Uterine film discharge experience as recalled by subject using a survey to be asked to the patient At second look hysteroscopy: 4-8 weeks
Secondary Device Manipulation Device manipulation duration from insertion to withdrawal. During intervention: T=0
Secondary Womed Leaf Discharge Feedback Questionnaire (Polymer Tolerance Assessed on a Scale From 1 (no Discomfort) to 10 (Extremely Disturbing)) Uterine film discharge experience as recalled by subject using a survey to be asked to the patient At second look hysteroscopy: 4-8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04972032 - Efficacy of Estrogen-intrauterine Stent System After Intrauterine Adhesiolysis N/A
Recruiting NCT03381807 - Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion Early Phase 1
Recruiting NCT03329898 - Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion N/A
Completed NCT03724617 - Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium N/A
Recruiting NCT03330873 - The Efficacy and Safety of Disposable Balloon Uterine Stent in Patients With Asherman Syndrome N/A
Completed NCT02220621 - Efficacy and Safety of Crosslinked Hyaluronan Gel for Preventing Intrauterine Adhesion N/A
Active, not recruiting NCT04963179 - PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film. N/A
Recruiting NCT03351205 - The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Recruiting NCT03346317 - Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Completed NCT05414760 - Evaluate Formation of IUAs After Third-generation Endometrial Ablation, With and Without Intrauterine Adhesion Barrier N/A
Completed NCT04166500 - Early Outpatient Hysteroscopy Can Prevent Intrauterine Adhesion After Induced Abortion N/A
Recruiting NCT03171454 - Immediate and Delayed Intrauterine Balloon in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Recruiting NCT03169478 - Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopic Myomectomy N/A
Recruiting NCT05003869 - Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions N/A
Completed NCT02744716 - Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion N/A
Completed NCT03131596 - Postoperative Intermittent Intrauterine Balloon Dilatation Therapy. N/A
Completed NCT04824430 - Assessment of Uterine Access, Uterine Patency and Intrauterine Adhesions Following Endometrial Ablation
Completed NCT01167296 - Safety of Leaving Cook Balloon Uterine Stent in Uterus for One Month Phase 4
Completed NCT03578172 - HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients N/A
Recruiting NCT04930913 - Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions